UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~December~~February 2224, ~~2016~~2017

FluoroPharma Medical, Inc.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

333-151381		20-8325616
(Commission File Number)		(IRS Employer Identification No.)

8 Hillside Avenue, Suite 108

Montclair, NJ 07042

(Address of principal executive offices and zip code)

(973) 744-1565

(Registrant's telephone number including area code)

(Registrant's former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2 1.0301.

~~Creation of~~Entry into a ~~Direct~~Material ~~Financial Obligation or an Obligation under an~~Definitive ~~Off-Balance Sheet Arrangement of a Registrant~~Agreement.

OnEffective ~~December~~as ~~22,~~of ~~2016~~February 24, ~~FluoroPharma Medical~~2017, ~~Inc.~~Platinum ~~(the “Company”) borrowed $50~~Montaur,~~000~~ inon ~~the~~behalf ~~form~~ of aitself ~~promissory~~and ~~note~~each ~~(the~~of ~~“Note”).~~its ~~The~~successors ~~Note~~and ~~matures~~assigns, onwaived ~~January~~its ~~31,~~Preferred ~~2017~~Ratchet Rights and ~~bears~~Warrant ~~interest~~Ratchet atRights ~~the~~with ~~rate~~respect ofto ~~10%~~the ~~per~~Subsequent Financing; ~~annum~~provided, ifhowever, ~~the~~that ~~Note~~such iswaiver shall ~~repaid~~be onautomatically orrevoked ~~prior~~and toof ~~the~~no ~~maturity~~further ~~date~~force and ~~15%~~effect if the Subsequent ~~Note~~Financing is not ~~repaid~~ completed by ~~the~~August ~~maturity date. The Note~~10, ~~contains the following event of default provisions:~~2017.

●The Preferred Ratchet Rights allowed Platinum Montaur, in its reasonable discretion, to exchange the Preferred Shares then held by it, valued at their stated value, together with accrued but unpaid dividends, for securities issued or to be issued in the Subsequent Financing, if the Company enters into any Subsequent Financing on terms more favorable than the terms governing the sale of the Preferred Stock.

The Warrant ~~Company~~Ratchet ~~fails~~Rights toallowed ~~pay~~Platinum Montaur, during the term of the Warrant, in the event the Company shall issue any Additional ~~installment~~Shares of ~~principal~~Common ~~under~~Stock or Convertible Securities at a price per share less than the ~~Note~~Exercise ~~within~~Price ~~ten~~then ~~(10)~~in ~~days~~effect ~~after~~or without consideration, then the Exercise Price upon each such ~~amounts~~issuance shall ~~are~~be ~~due;~~adjusted to the price equal to the consideration per share paid for such Additional Shares of Common Stock or Convertible Securities.

●A Subsequent Financing is if the Company effectuates a Subsequent Financing, on terms more favorable than the terms governing the sale of the Preferred Stock under the Purchase Agreement, pursuant to which it may issue Additional Shares of Common Stock or Convertible Securities at a price per share less than the Exercise Price in the Warrant .

~~The Company~~ ~~breaches any material covenant or other term or condition of the~~Item ~~Note, except for a breach of payment, in any material respect and such breach, if subject to cure, continues for a period of twenty (20) days after written notice to the Company from the Lender;~~3.03.

●Material Modifications to Rights of Security Holders

~~Any dissolution,~~ ~~liquidation~~The disclosure orset ~~winding~~forth upunder byItem ~~the~~1.01 ~~Company~~above oris ahereby ~~Subsidiary~~incorporated in ofits ~~a substantial~~entirety ~~portion~~under ofthis ~~their~~Item ~~business;~~3.03.

●Item 5.02.

Any cessation of operations by the Company or a Subsidiary;

●

Any money judgment, writ or similar final process shall be entered or made in a non-appealable adjudication against the Company or any Subsidiary or any of its property or other assets for more than $250,000 in excess of the Company’s insurance coverage, unless stayed vacated or satisfied within 60 days;

●

The Company files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes any corporate action in furtherance of any of the foregoing; and

●

An involuntary petition is filed against the Company under any bankruptcy statute now or hereafter in effect, and such petition is not dismissed or discharged within 60 days, or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official) is appointed to take possession, custody or control of any property of the Company.

The foregoing description of the Note is qualified in its entirety by reference to the complete text of the form of the form of Note filed as Exhibit 4.1 hereto.

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~Effective~~ Effective as of ~~January~~February 19, 2017, DrMr. ~~Peter~~Lawrence ~~Conti~~Atinsky ~~and~~resigned ~~Johan (Thijs) Spoor~~as ~~agreed~~a todirector. Mr. ~~resign~~Atinsky aswas ~~directors.~~on ~~The~~the ~~resignations~~audit committee of ~~Dr.~~the Board ~~Conti~~of Directors and ~~Mr.~~ ~~Spoor~~the ~~are~~compensation ~~not~~committee ~~due~~of tothe ~~any~~Board ~~disagreements~~of ~~on any matter relating~~Directors toat the ~~Company’s~~time ~~operations,~~of ~~policies~~his ~~and practices~~resignation.

Mr. Atinsky has been provided a copy of this Current Report on Form 8-K as of the date of this Current Report and has been provided the opportunity to furnish to the Company as promptly as possible a letter addressed to the Company stating whether he agrees with the statements made by the Company in this Current Report, and if not, stating the respects in which he does not agree. The Company will file any such letter, if it is received from Mr. Atinsky, within two business days of receipt.

Item 9.01

Financial Statement and Exhibits.

(d) Exhibits.

Exhibit No.		Description
4.1		Form of Note.
10.1		Waiver

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.  

Dated: ~~December~~March 292, ~~2016~~2017 FLUOROPHARMA MEDICAL, INC. By: /s/ Thomas H. Tulip Name: Thomas H. Tulip Title: CEO and President

EXHIBIT INDEX

Exhibit No.		Description
4.1		Form of Note.

(d) Exhibits.

Exhibit No.		Description
10.1		Waiver

Filing Compare · FLUOROPHARMA MEDICAL, INC.